
|Articles|February 1, 2004
- Pharmaceutical Executive-02-01-2004
Upping the Ante
With overworked execs and underfunded campaigns, it is hard to believe that the ad industry has the resources to improve its creativity while churning out campaigns better, faster, and cheaper. But this year?s Rx Club Awards winners show that a more sophisticated and risqué style is emerging?direct in message, clear on benefit, and confident in execution.
Advertisement
Articles in this issue
almost 22 years ago
February Table of Contentsalmost 22 years ago
Knowing When to Pull the Plug On Your Experimental DrugNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
3
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
4
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
5





